Characteristics of different subgroups of patients with PMBL: patients with PMBL with high gene expression of both PDL1/PDL2 genes (PDL1high/PDL2high) and patients with PMBL with B2M mutations
| . | NGS set n = 128 . | GEP set n = 120 . | ||||
|---|---|---|---|---|---|---|
| B2M mutated, n = 81 . | Wild-type B2M, n = 47 . | Adjusted P value . | PDL1high/PDL2high, n = 37 . | Other, n = 83 . | Adjusted P value . | |
| Age (median [min-max]), y | 32 (18-64) | 36 (19-67) | .581 | 34 (18-67) | 35 (26-44) | .802 |
| Age > 60 y | 2 (2.5%) | 3 (6.4%) | .534 | 1 (2.7%) | 3 (3.6%) | 1 |
| Female | 50 (61.7%) | 22 (46.8%) | .303 | 20 (54.1%) | 50 (60.2%) | .526 |
| ECOG performance status score of 0 to 1 | 68 (85.0%) | 40 (87.0%) | .97 | 30 (81.1%) | 72 (87.8%) | .738 |
| Ann Arbor stage I to II | 45 (55.6%) | 23 (48.9%) | .557 | 16 (43.2%) | 50 (60.2%) | .252 |
| Presence of an anterior mediastinal involvement | 81 (100%) | 47 (100%) | 1 | 37 (100%) | 83 (100%) | 1 |
| Elevated LDH level | 68 (84.0%) | 34 (72.3%) | .157 | 35 (94.6%) | 64 (77.1%) | .062 |
| IPI 0 | 9 (11.4%) | 6 (13.3%) | .535 | 2 (5.4%) | 10 (12.3%) | .141 |
| IPI 1 to 2 | 47 (59.5%) | 30 (66.7%) | 21 (56.8%) | 55 (67.9%) | ||
| IPI 3 to 5 | 23 (29.1%) | 9 (20.0%) | 14 (37.8%) | 16 (19.8%) | ||
| Bulky mass ≥ 10 cm | 51 (63.8%) | 25 (54.3%) | .739 | 24 (64.9%) | 50 (61.0%) | .739 |
| Baseline median MTV, cm3 (min-max) | 294.4 (15.7-1147.5) | 245.7 (46.5-734) | .443 | 358.5 (19.3-1147.5) | 255.7 (15.7-1066.3) | .081 |
| Maximal median mass diameter, mm (min-max) | 106 (10.1-180) | 100 (10.9-140) | .305 | 107 (70-175) | 100 (10-180) | .305 |
| Extranodal involvement | 42 (51.9%) | 26 (56.5%) | .918 | 22 (59.5%) | 40 (48.2%) | .762 |
| Top 3 most frequently mutated genes | B2M (100%) SOCS1 (92.6%) TNFAIP3 (56.8%) | SOCS1 (78.7%) STAT6 (70.2%) IGLL5 (57.4%) | SOCS1 (85.3%) B2M (67.6%) ITPKB (55.9%) | SOCS1 (86.5%) B2M (63.5%) TNFAIP3 (54%) | ||
| Firstline treatment | ||||||
| Anti-CD20 + ACVBP | 53 (65.4%) | 26 (55.3%) | .788 | 26 (70.3%) | 54 (65.1%) | .874 |
| Anti-CD20 + CHOP14 | 16 (19.8%) | 12 (25.5%) | 7 (18.9%) | 17 (20.5%) | ||
| Anti-CD20 + CHOP21 | 12 (14.8%) | 9 (19.1%) | 4 (10.8%) | 12 (14.5%) | ||
| MTV of ≥360 cm3 | 22 (36.7%) | 11 (31.4%) | .605 | 15 (48.4%) | 19 (29.7%) | .225 |
| Median follow-up, mo (min-max) | 43.6 (1-143.5) | 60.2 (7.7-152.7) | .195 | 50.6 (1-152.7) | 47.2 (5-143.5) | .957 |
| . | NGS set n = 128 . | GEP set n = 120 . | ||||
|---|---|---|---|---|---|---|
| B2M mutated, n = 81 . | Wild-type B2M, n = 47 . | Adjusted P value . | PDL1high/PDL2high, n = 37 . | Other, n = 83 . | Adjusted P value . | |
| Age (median [min-max]), y | 32 (18-64) | 36 (19-67) | .581 | 34 (18-67) | 35 (26-44) | .802 |
| Age > 60 y | 2 (2.5%) | 3 (6.4%) | .534 | 1 (2.7%) | 3 (3.6%) | 1 |
| Female | 50 (61.7%) | 22 (46.8%) | .303 | 20 (54.1%) | 50 (60.2%) | .526 |
| ECOG performance status score of 0 to 1 | 68 (85.0%) | 40 (87.0%) | .97 | 30 (81.1%) | 72 (87.8%) | .738 |
| Ann Arbor stage I to II | 45 (55.6%) | 23 (48.9%) | .557 | 16 (43.2%) | 50 (60.2%) | .252 |
| Presence of an anterior mediastinal involvement | 81 (100%) | 47 (100%) | 1 | 37 (100%) | 83 (100%) | 1 |
| Elevated LDH level | 68 (84.0%) | 34 (72.3%) | .157 | 35 (94.6%) | 64 (77.1%) | .062 |
| IPI 0 | 9 (11.4%) | 6 (13.3%) | .535 | 2 (5.4%) | 10 (12.3%) | .141 |
| IPI 1 to 2 | 47 (59.5%) | 30 (66.7%) | 21 (56.8%) | 55 (67.9%) | ||
| IPI 3 to 5 | 23 (29.1%) | 9 (20.0%) | 14 (37.8%) | 16 (19.8%) | ||
| Bulky mass ≥ 10 cm | 51 (63.8%) | 25 (54.3%) | .739 | 24 (64.9%) | 50 (61.0%) | .739 |
| Baseline median MTV, cm3 (min-max) | 294.4 (15.7-1147.5) | 245.7 (46.5-734) | .443 | 358.5 (19.3-1147.5) | 255.7 (15.7-1066.3) | .081 |
| Maximal median mass diameter, mm (min-max) | 106 (10.1-180) | 100 (10.9-140) | .305 | 107 (70-175) | 100 (10-180) | .305 |
| Extranodal involvement | 42 (51.9%) | 26 (56.5%) | .918 | 22 (59.5%) | 40 (48.2%) | .762 |
| Top 3 most frequently mutated genes | B2M (100%) SOCS1 (92.6%) TNFAIP3 (56.8%) | SOCS1 (78.7%) STAT6 (70.2%) IGLL5 (57.4%) | SOCS1 (85.3%) B2M (67.6%) ITPKB (55.9%) | SOCS1 (86.5%) B2M (63.5%) TNFAIP3 (54%) | ||
| Firstline treatment | ||||||
| Anti-CD20 + ACVBP | 53 (65.4%) | 26 (55.3%) | .788 | 26 (70.3%) | 54 (65.1%) | .874 |
| Anti-CD20 + CHOP14 | 16 (19.8%) | 12 (25.5%) | 7 (18.9%) | 17 (20.5%) | ||
| Anti-CD20 + CHOP21 | 12 (14.8%) | 9 (19.1%) | 4 (10.8%) | 12 (14.5%) | ||
| MTV of ≥360 cm3 | 22 (36.7%) | 11 (31.4%) | .605 | 15 (48.4%) | 19 (29.7%) | .225 |
| Median follow-up, mo (min-max) | 43.6 (1-143.5) | 60.2 (7.7-152.7) | .195 | 50.6 (1-152.7) | 47.2 (5-143.5) | .957 |
Abbreviations are explained in Table 1.